Ben Gewurz
banner
bgewurz.bsky.social
Ben Gewurz
@bgewurz.bsky.social
George and Sandra K. Schussel Associate Professor. Associate Chair, Program in Virology. Interested in Epstein-Barr virus, B cells, cancer, lymphoma, gastric cancer, nasopharyngealcarcinoma, immunometabolism, CRISPR, multiple sclerosis
They were an excellent model for EBV lymphoma Genesis, because they became endangered, the research had to stop
February 27, 2025 at 11:28 PM
I thought marmosets are endangered and that research on them has not been allowed? They are infectible by Epstein-Barr virus, it would be an interesting multiple sclerosis model if they were not endangered
February 27, 2025 at 11:07 PM
Congratulations on your new position Mandy
February 26, 2025 at 3:04 AM
But equally so for the publishers, like Elsevier
February 22, 2025 at 4:38 AM
Interesting that the FACT inhibitor cbl0137 blocks hepatitis B replication, but instead reactivates Epstein-Barr virus by inhibiting expression of the oncogene MYC
February 20, 2025 at 7:58 PM
Reposted by Ben Gewurz
CRISPR-Cas, cheap genomic sequencing, mRNA vaccines and other products, paired with AI protein folding prediction technology (eg Alphafold) are the likely core of the next big thing. and it's where a big chunk of 2 decades of US R&D have gone. Cumulative US R&D by top spenders / by sector, 2004-2023
February 8, 2025 at 3:32 PM